Inhibition of p38MAPK potentiates mesenchymal stem cell therapy against myocardial infarction injury in rats

  • Authors:
    • Zhiling Zhang
    • Shulan Zhou
    • Zhiliang Mei
    • Ming Zhang
  • View Affiliations

  • Published online on: July 14, 2017     https://doi.org/10.3892/mmr.2017.6973
  • Pages: 3489-3493
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the protective effect of mesenchymal stem cell (MSC) therapy in combination with p38 mitogen‑activated protein (MAPK) inhibition against myocardial infarction (MI) injury in rats, and to elucidate the underlying mechanisms. An MI model was established by ligation of the anterior descending branch of the left coronary artery. The rats were divided into four groups: MSC transplantation, p38MAPK inhibitor (SB203580), MSC + SB203580 and model control group. HE staining and a TUNEL assay were performed to evaluate pathological changes and apoptosis. The expression levels of p38MAPK and transforming growth factor β‑activated kinase 1 (TAK1) were determined using reverse transcription‑polymerase chain reaction and western blot analyses. As shown by HE staining, classical morphological changes, including irregular cell arrangement and inflammatory infiltration were observed in the model rats, whereas MSC therapy or injection of the p38MAPK inhibitor ameliorated these pathological changes. Of note, the combined application of MSCs with the p38MAPK inhibitor exerted additive effects. The TUNEL assay showed that the combined application of MSCs with p38MAPK inhibitor also led to potentiation of effects, compared with either MSCs therapy or p38MAPK inhibitor injection alone. Mechanistically, the combined application of MSCs with p38MAPK inhibitor decreased the expression levels of TAK1 and p38MAPK at the mRNA and protein levels. In conclusion, p38MAPK inhibition potentiated the protective effects of MSCs therapy against MI in rats.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 16 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Z, Zhou S, Mei Z and Zhang M: Inhibition of p38MAPK potentiates mesenchymal stem cell therapy against myocardial infarction injury in rats. Mol Med Rep 16: 3489-3493, 2017.
APA
Zhang, Z., Zhou, S., Mei, Z., & Zhang, M. (2017). Inhibition of p38MAPK potentiates mesenchymal stem cell therapy against myocardial infarction injury in rats. Molecular Medicine Reports, 16, 3489-3493. https://doi.org/10.3892/mmr.2017.6973
MLA
Zhang, Z., Zhou, S., Mei, Z., Zhang, M."Inhibition of p38MAPK potentiates mesenchymal stem cell therapy against myocardial infarction injury in rats". Molecular Medicine Reports 16.3 (2017): 3489-3493.
Chicago
Zhang, Z., Zhou, S., Mei, Z., Zhang, M."Inhibition of p38MAPK potentiates mesenchymal stem cell therapy against myocardial infarction injury in rats". Molecular Medicine Reports 16, no. 3 (2017): 3489-3493. https://doi.org/10.3892/mmr.2017.6973